CA3207440A1 - Amiselimod for preventing, treating, or ameliorating ulcerative colitis - Google Patents
Amiselimod for preventing, treating, or ameliorating ulcerative colitis Download PDFInfo
- Publication number
- CA3207440A1 CA3207440A1 CA3207440A CA3207440A CA3207440A1 CA 3207440 A1 CA3207440 A1 CA 3207440A1 CA 3207440 A CA3207440 A CA 3207440A CA 3207440 A CA3207440 A CA 3207440A CA 3207440 A1 CA3207440 A1 CA 3207440A1
- Authority
- CA
- Canada
- Prior art keywords
- dose
- subject
- amiselimod
- administration
- administration period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Luminescent Compositions (AREA)
- Cereal-Derived Products (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163147060P | 2021-02-08 | 2021-02-08 | |
| US63/147,060 | 2021-02-08 | ||
| PCT/EP2022/053030 WO2022167690A1 (en) | 2021-02-08 | 2022-02-08 | Amiselimod for preventing, treating, or ameliorating ulcerative colitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3207440A1 true CA3207440A1 (en) | 2022-08-11 |
Family
ID=80447376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3207440A Pending CA3207440A1 (en) | 2021-02-08 | 2022-02-08 | Amiselimod for preventing, treating, or ameliorating ulcerative colitis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240299318A1 (https=) |
| EP (1) | EP4288041A1 (https=) |
| JP (1) | JP2024506041A (https=) |
| CN (1) | CN116940350A (https=) |
| AU (1) | AU2022217475A1 (https=) |
| CA (1) | CA3207440A1 (https=) |
| MX (1) | MX2023009249A (https=) |
| TW (1) | TW202245742A (https=) |
| WO (1) | WO2022167690A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025134072A1 (en) * | 2023-12-21 | 2025-06-26 | Bausch Health Ireland Limited | Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| BRPI0619894B8 (pt) | 2005-12-15 | 2021-05-25 | Mitsubishi Tanabe Pharma Corp | composto de amina e composição farmacêutica |
| JP5657565B2 (ja) | 2008-12-22 | 2015-01-21 | ノバルティス アーゲー | Ｓ１ｐ受容体アゴニストの投与レジメン |
| MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| PL3242666T3 (pl) * | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| JP2018527406A (ja) * | 2015-08-11 | 2018-09-20 | アカール ファーマ ピーティーワイ リミテッドＡｋａａｌ Ｐｈａｒｍａ Ｐｔｙ Ｌｔｄ | Ｓ１ｐ受容体モジュレーターを含む組成物 |
| WO2020051568A1 (en) * | 2018-09-08 | 2020-03-12 | Wen Tan | NEW USE OF R-ENANTIOMER OF ADRENERGIC β2 RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND ITS EXTRA INTESTINAL MANIFESTATIONS |
-
2022
- 2022-02-08 AU AU2022217475A patent/AU2022217475A1/en active Pending
- 2022-02-08 WO PCT/EP2022/053030 patent/WO2022167690A1/en not_active Ceased
- 2022-02-08 CN CN202280013674.8A patent/CN116940350A/zh active Pending
- 2022-02-08 CA CA3207440A patent/CA3207440A1/en active Pending
- 2022-02-08 MX MX2023009249A patent/MX2023009249A/es unknown
- 2022-02-08 EP EP22705759.3A patent/EP4288041A1/en active Pending
- 2022-02-08 JP JP2023547694A patent/JP2024506041A/ja active Pending
- 2022-02-08 US US18/276,120 patent/US20240299318A1/en active Pending
- 2022-02-08 TW TW111104482A patent/TW202245742A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4288041A1 (en) | 2023-12-13 |
| CN116940350A (zh) | 2023-10-24 |
| TW202245742A (zh) | 2022-12-01 |
| JP2024506041A (ja) | 2024-02-08 |
| WO2022167690A1 (en) | 2022-08-11 |
| AU2022217475A1 (en) | 2023-08-24 |
| MX2023009249A (es) | 2023-10-23 |
| US20240299318A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6244497B1 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP6309454B2 (ja) | 癌の併用処置 | |
| JP4938905B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| KR101801864B1 (ko) | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 | |
| CA2829947A1 (en) | Dosing regimens for the treatment of fabry disease | |
| WO2010042548A2 (en) | Methods of treating inflammation | |
| KR102495432B1 (ko) | 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도 | |
| TW200800206A (en) | Methods for determining how to treat congestive heart failure | |
| JP2024531314A (ja) | 小児ｍｓを治療するためのオファツムマブ | |
| US20240299318A1 (en) | Amiselimod for preventing, treating or ameliorating ulcerative colitis | |
| JP7713489B2 (ja) | Ｂ因子阻害剤の使用方法 | |
| JP6890340B6 (ja) | グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法 | |
| JP2025106329A (ja) | ベンラリズマブを使用した強化された患者個体群における慢性閉塞性肺疾患を治療するための方法 | |
| WO2025134072A1 (en) | Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod | |
| JP2018135278A (ja) | 循環器疾患及び／又はミトコンドリア病の改善用医薬 | |
| EA051860B1 (ru) | Способ профилактики, лечения или облегчения язвенного колита | |
| HK40094222A (zh) | 预防、治疗或改善溃疡性结肠炎的阿米莫德 | |
| JP2021510157A (ja) | 内皮細胞機能障害を調節するためのｒｐｓ２ペプチドの使用 | |
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| WO2021203013A2 (en) | Methods of treating immune mediated pulmonary injury | |
| KR20220074913A (ko) | S1p1 수용체와 관련된 상태를 치료하는 방법 | |
| WO2025209479A1 (en) | Methods of treatment of immune thrombocytopenia using sovleplenib | |
| EP4616867A1 (en) | Combination of endothelin receptor antagonist and glucocorticoid for treating iga nephropathy | |
| Home | Highlights in Ulcerative Colitis From the 18th Congress of ECCO | |
| TW202539688A (zh) | 使用索樂匹尼布處置溫型自體免疫性溶血性貧血的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250124 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250124 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250124 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260109 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260109 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260109 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260122 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260122 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260219 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260219 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260219 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260219 |